All posts by: Michael Zand

About Michael Zand

Review: ‘Passengers’ under-performs its sizable budget – Daily American Online

Continue reading

2017-01-10 NEWS

Review: ‘Passengers’ under-performs its sizable budget
Daily American Online
The travelers were eager enough for a new beginning that they abandoned all worldly friendships and associations, and submitted themselves to suspended animation, enforced hibernation, for the 120-year voyage to the distant Homestead II planet.

and more »

Continue reading

2017-01-10 NEWS

Counsel & Heal

Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Yahoo Finance
Roche Holding AG’s RHHBY Genentech announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients suffering from …
FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder CancerCounsel & Heal

all 4 news articles »

Continue reading

2017-01-10 NEWS

Paris Post Intelligencer

Local doctor first in area to do stem cell transplants
Paris Post Intelligencer
The biggest advantage stem cell injections seem to offer over more invasive arthritis remedies is a quicker, easier recovery — the procedure is done on an outpatient basis, and the majority of patients are up and moving within only 24 hours with

Continue reading

2017-01-10 NEWS

Immuno-Oncology News

Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
Immuno-Oncology News
Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll …
Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro’s CRS-207 With …Clinical Leader

all 5 news articles »

Continue reading

2017-01-10 NEWS

Community Financial News

Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
Immuno-Oncology News
Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll …
Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro’s CRS-207 With …Clinical Leader

all 5 news articles »

Continue reading

2017-01-10 NEWS

Counsel & Heal

FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder Cancer
Counsel & Heal
On January 2017, FDA has granted Tecentriq (atezolizumab) as a cancer immunotherapy drug. It has been evaluated as the first-line treatment option for people not eligible for cisplatin chemotherapy. The drug is also intended for people who are either …
Roche Gets Priority Review for Immunotherapy Drug TecentriqZacks.com

all 3 news articles »